Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Mario Airoldi et al.|The Lancet|2018Cited by 1.7k
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trialJohann S. de Bono, Ulrik Lassen, Nicole Concin et al.|The Lancet Oncology|2019Cited by 228
Representative Sequencing: Unbiased Sampling of Solid Tumor TissueKevin Litchfield, Ron Sinclair, Stacey Stanislaw et al.|Cell Reports|2020Cited by 77
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung CancerLauren A. Byers, Martin Förster, Alejandro Navarro et al.|Clinical Lung Cancer|2021Cited by 39
An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical TrialsDavid J. Pinato, Sarah P. Blagden, Chara Stavraka et al.|PLoS ONE|2014Cited by 33